Autophagy and toll-like receptors: A new link in cancer cells

Autophagy

Volumn 4, Issue 8, 2008, Pages 1086-1089

  Bertin, Samuel ^a,b   Pierrefite Carle, Valérie ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Autophagy; Bacterial DNA; CpG ODN; TLR9; Tumor cells

Indexed keywords

LIPOPOLYSACCHARIDE; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9;

ARTICLE; AUTOPHAGY; BACTERIAL GENE; BACTERIUM; CANCER CELL; CANCER THERAPY; CPG ISLAND; ELECTRIC POTENTIAL; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; PATHOGENESIS; RECOGNITION; RODENT; TISSUE; TUMOR CELL; TUMOR CELL LINE; WORK;

BACTERIA (MICROORGANISMS); RODENTIA;

EID: 58149090542     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.7138     Document Type: Article

References (30)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
2. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007; 27:135-44.
3. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. EMBO J 2008; 27:1110-21.
4. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira, S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5.
5. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-60.
6. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84.
7. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20:1130-7.
8. Bohnhorst J, Rasmussen T, Moen SH, Fløttum M, Knudsen L, Børset M, Espevik T, Sundan A. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20:1138-44.
9. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley, B, Harris KW, Selander KS. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006; 4:437-47.
10. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 2006; 5:2106-14.
11. Rayburn ER, Wang W, Zhang Z, Li M, Zhang R, Wang H. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: Effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 2006; 66:1653-63.
12. Andaloussi AE, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006; 54:526-35.
13. Colell A, Ricci JE, Tait S, Milasta S, Maurer U, Bouchier-Hayes L, Fitzgerald P, Guio-Carrion A, Waterhouse NJ, Li CW, Mari B, Barbry P, Newmeyer DD, Beere HM, Green DR. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007; 129:983-97.
14. Deretic V. Autophagy as an immune defense mechanism. Curr Opin Immunol 2006; 18:375-82.
15. Bertin S, Samson M, Pons C, Guigonis JM, Gavelli A, Baque P, Brossette N, Pagnotta S, Ricci JE, Pierrefite-Carle V. Comparative proteomics study reveals that bacterial CpG motifs induce tumor cell autophagy in vitro and in vivo. Mol Cell Proteomics 2008; In press.
16. Werling D, Hope JC, Howard CJ, Jungi TW. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists. Immunology 2004; 111:41-52.
17. Sanchez-Campillo M, Chicano A, Torío A, Martín-Orozco E, Gámiz P, Hernández-Caselles T, García-Peñarrubia P. Implication of CpG-ODN and reactive oxygen species in the inhibition of intracellular growth of Salmonella typhimurium in hepatocytes. Microbes Infect 2004; 6:813-20.
18. Djavaheri-Mergny M, Amelotti M, Mathieu J, Besançon F, Bauvy C, Souquère S, Pierron G, Codogno P. NF-κB activation represses tumor necrosis factor-a-induced autophagy. J Biol Chem 2006; 281:30373-82.
19. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res 2005; 8:3-5.
20. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cell. Science 2007; 315:1398-401.
21. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 2008; 28:799-809.
22. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190-8.
23. Leifer CA, Brooks JC, Hoelzer K, Lopez J, Kennedy MN, Mazzoni A, Segal DM. Cytoplasmic targeting motifs control localization of toll-like receptor 9. J Biol Chem 2006; 281:35585-92.
24. Reggiori F. Membrane origin for autophagy. Curr Top Dev Biol. 2006; 74:1-30.
25. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23:2891-906.
26. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008; 27:234-43.
27. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, Kreymborg K, Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG, Stevanovic S. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA 2005; 102:7922-7.
28. Schmid D, Pypaert M, Münz C. MHC class II antigen loading compartments continuously receive input from autophagosomes. Immunity 2007; 26:79-92.
29. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007; 179:2493-500.
30. Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanovic S. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 2006; 12:4163-70.